Pr Anthony BUISSON

[Malcolm Tan @IBDGastroDocSg]

Do IBD patients with BMI>30 kg/m² require higher subcutaneous IFX doses?

- post-hoc REMSWITCH analysis suggests not
- patients were already in clinical remission
- no patient BMI>30 kg/m² developed anti-IFX antibodies
- not just a biosimilar but "bio-better"?

[Shomron Ben-Horin @ShomronH]

Encouraging results in post-hoc analysis of Upa in CD perianal fistulas.
Yet bewildering how 20yrs later, IFX ACCENT2 trial is still the only pharmaceutical RCT in perianal dis!!. In essence this makes all other biologics/SM we give to these pts to be somewhat off-label...

[Journal of Crohn's and Colitis @JCC_IBD]

The GETAID: 40 years of a family story in IBD. Laharie et al. @BouhnikYoram @JeanFredericCo1 @MatFume @PeyrinBiroulet https://t.co/istwStUPf6

[Pr Anthony BUISSON @BuissonPr]

DEVISE-CD project in @AGA_CGH
A new MRI score (C-score) dedicated to define and assess transmural healing and response in patients with CD.
C-score is now a validated, reliable and easy-to-use tool to assess therapeutic efficacy.
https://t.co/5ZhzmhqQz5

[Beatriz Gros @Bealoquebea]

PREDICT UC trial optimizing infliximab dose in patients with #ASUC

Initially no differences at day 8 BUT
✅intensified better if albumin<25
✅ intensified better if crp>50

Presented by Matthew Chuen Seng Choy at @DDWMeeting #DDW2024

[Nathalie Rolhion @NRolhion]

Clermont Ferrand aux couleurs des MICI

@ClermontFd @afaCrohnRCH

💜 @M2ISH_UCA 💜

[afa-Crohn-RCH @afaCrohnRCH]

🟠Tension d'approvisionnement de Questran : l'afa se bat ! Le point sur la situation : https://t.co/xOfGlXlueN

[Mathurin Fumery @MatFume]

Le GETAID souffle ses 40 bougies

https://t.co/Da0lfLhPuJ

[Pr Anthony BUISSON @BuissonPr]

Happy to publish long-term results of the REMSWITCH study in AP&T confirming that switching from IV to SC infliximab is safe and well-accepted for IBD patients treated with intensified IV regimen and providing practical algorithm to help IBD physicians to safely manage the switch

[roypounder.apt @APandT]

@APandT - "Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study" - https://t.co/H5prpZAQYc
#GItwitter #IBD #infliximab

[Jean-Frederic Colombel @JeanFredericCo1]

Celebrating 25 years of Adhesive Invasive E. coli
Starting with tribute to our beloved Arlette Darfeuille-Michaud

[Mathurin Fumery @MatFume]

Chers amis gastro, nous avons besoin de vous !
Le GETAID lance ICARE II
▶️évaluer en vie réelle la tolérance des nouveaux traitements des MICI
▶️ Tous les gastroentérologues en France peuvent participer
✅ Concept du patient chercheur
Inscription lien ou MP

[Jean-Frederic Colombel @JeanFredericCo1]

- Took years to recruit bionaive patients !
- Rationale combination needed to be transformative
- Bayesian analysis should be used more for POC studies

Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER) https://t.co/A2Rlifpi4s

[CGH @AGA_CGH]

Study examines effectiveness of switching from intravenous to subcutaneous infliximab in patients with #IBDs. Learn more at https://t.co/3rjxV7WaEW

[afa-Crohn-RCH @afaCrohnRCH]

Les MICI, maladies environnementales ? Le Pr Anthony Buisson nous répond sur l'afa web tv.
👉 https://t.co/XMdl30ddwF

[afa-Crohn-RCH @afaCrohnRCH]

L'afa est à #Chicago pour rencontrer des experts #MICI Français et internationaux à l'occasion de l'exceptionnel Congrès #ddw23 !
Les nouveautés et les interviews des professionnels de santé seront bientôt disponibles sur notre chaîne Youtube afa web tv, pensez à vous abonner 😉

[Pr Anthony BUISSON @BuissonPr]

@mchiorean4 More details will follow with the full article...

[Pr Anthony BUISSON @BuissonPr]

@Bealoquebea @MatFume Happy to help IBD physicians to chose the most appropriate treatment for our patients.

[Mathurin Fumery @MatFume]

@DCharabaty @bruce_sands1 @IBDConference @ibddoctor @mchiorean4 @UmaMahadevanIBD @JeanDonet @joshsteinbergMD @Waseem_AhmedMD @SchairerIBDMD @IBDimmunology @MRegueiroMD @EdwardLoftus2 @ibdgijami The GETAID study will be published in the coming days in @APandT. In about 100 patients with anti-TNF, vedo and ustekinumab failure, risankizumab induction : clinical response > 70% of patients and remission in 50% @PGetaid @PeyrinBiroulet

[Pr Anthony BUISSON @BuissonPr]

Happy to share with you the results of our real-world comparison between tofacitinib and vedolizumab after anti-TNF failure in UC published in @APandT
https://t.co/vzbAxo97B3

[Shomron Ben-Horin @ShomronH]

Clever ACCEPT2 study. 1850pts survey by @BuissonPr @MatFume. Shows pts preference for oral Tx is not automatic but depends on interval of SC injections. So, e8W (but not e2W) is preferred even over once daily oral pill by experienced pts. @IBDJournals
https://t.co/b8MoYz4fJZ